Impact on microbiology laboratory turnaround times following process improvements and total laboratory automation.

Carolyn Gonzalez-Ortiz, M(ASCP)[CM],[1] Alanna Emrick, MLS(ASCP)[CM] SM[CM], [1] Ying P. Tabak, PhD,[2] Latha Vankeepuram, MS,[2] Stephen Kurtz, MS,[2] David Sellers, BS,[2] Megan Wimmer, MBA,[2] Caitlin Asjes, MS,[2] Suhaireirene Suady Barake, MD,[3] Jacob Nichols, MD,[3] Fatma Levent, MD[3#]

Affiliations:

[1] University Medical Center, Lubbock, TX

[2] Becton, Dickinson and Company, Franklin Lakes, NJ

[3]Texas Tech University Health Sciences Center, Lubbock, TX

#To whom correspondence should be addressed:

Fatma Levent, MD, Clinical Associate Professor

Pediatric Infectious Diseases / Department of Pediatrics

Texas Tech Health Sciences Center

Lubbock, TX

Phone: 806-392-4976

Fax: 806-743-2314

Email: fatma.levent@ttuhsc.edu

Source of support: This work was supported in part by Becton, Dickinson and Company.

Running title: Improved lab efficiency with automation

Abbreviations: TLA, total laboratory automation; SOP, standard operating procedure; MALDI-TOF, matrix-assisted laser desorption ionization time-of-flight mass spectrometry; TAT,

turnaround time; ID, identification; ASM, American Society of Microbiology; CLSI, Clinical Laboratory Standards Institute; MT, medical technologist

ABSTRACT

Introduction: The impact of workflow changes and total laboratory automation (TLA) on microbiology culture processing time was evaluated in an academic-affiliated regional hospital.

Materials and Methods: A retrospective analysis of microbiological data in a research database was performed to compare turnaround time (TAT) for organism identification (ID) before and after implementation of TLA (2013 versus 2016, respectively). TAT was compared using the $\chi 2$ test for categorical variables and log-transformed t-test for continuous variables.

Results: A total of 9,351 predefined common and clinically important positive mono-bacterial culture results were included in the analysis. Shorter TAT (hours) in 2016 compared to 2013 ($p<0.0001$) for positive result pathogen ID were observed in specimen types including blood (51.2 vs. 70.6), urine (40.7 vs. 47.1), wound (39.6 vs. 60.2), respiratory (47.7 vs. 67), and all specimen types combined (43.3 vs. 56.8). Although shorter TATs were not observed from all specimen categories for negative result pathogen ID, TAT for all specimen types combined was shorter ($p\leq0.001$) in 2016 compared to 2013 (94 vs. 101).

Conclusions: Total laboratory automation and workflow changes—including process standardization—facilitate shorter organism ID TAT across specimen sources.

Key Words: Laboratory automation, Microbiology, Clinical laboratory, Laboratory workflow, Turnaround time

23 **INTRODUCTION**

24 Total laboratory automation (TLA) involves the integration of pre- and post-analytical processes
25 through incorporation of multiple, modular systems to perform different tests, on diverse
26 matrices, within the clinical microbiology laboratory, and typically consists of automation for
27 plating, incubation, reading, and processing of specimens. Through reduced manual processing
28 of specimens, standardization can be established to minimize the incidence of human error.[1]
29 Studies have demonstrated the clinical value of automating microbiological workflow including
30 enhanced microbial growth, better colony isolation, reduced requirements for bacterial
31 subculture, and reduced time to results.[2-6] Previous work suggests that TLA can facilitate rapid
32 reporting of microbiology culture testing, thereby informing the management of infectious
33 disease and leading to enhanced patient care.[6-8]
34
35 This need for laboratory automation comes from an increased demand for clinical microbiology
36 laboratory services, despite growing staffing challenges.[9-11] Successful automation of a
37 laboratory requires a thorough assessment and appropriate refinement of all laboratory workflow
38 practices that might impact system efficiency.[12, 13] This includes consideration of extending
39 service delivery to a twenty-four-hour day, seven days per week (24/7) schedule.[3, 13, 14] Such
40 changes facilitate the maximum benefit from laboratory automation.
41
42 Previous work demonstrated that TLA can also improve laboratory workflow, efficiency, and
43 reproducibility[6, 9, 15, 16] while reducing errors.[4, 8] Staffing reductions of approximately 30%
44 have been reported after automation despite a 27% increase in average laboratory workload per

45 day.[3] Thus, TLA addresses the challenges associated with a high volume workload and allows
46 managers to reallocate human resources to value-added activities.
47
48 In 2014, the University Medical Center (UMC), Lubbock, TX prioritized improvements to
49 quality and efficiency in the microbiology laboratory, including moving to TLA. After an
50 assessment of available TLA solutions, UMC leadership supported investment in the BD
51 Kiestra™ TLA system (Kiestra; Becton, Dickinson and Company, BD Life Sciences—BD
52 Integrated Diagnostic Systems, Sparks, MD, USA), which automates and standardizes sample
53 setup, incubation, and reading. UMC became the second laboratory in the United States to
54 implement Kiestra TLA and the first to both operate 24/7 as well as have all microbial sample
55 types on the system. Preparation for the transition to automation included changes in laboratory
56 policy and processes. The hypothesis here was that a combination of TLA and foundational
57 workflow improvements (made in anticipation of the new technology associated with TLA)
58 would result in a shorter post-TLA turnaround time (TAT). Although previous studies have
59 evaluated the use of TLA for single specimen sources,[5-7, 17-22] the goal here was to evaluate
60 TAT across a wide range of specimen sources.

61 **MATERIALS AND METHODS**

62 Study Design

63 We compared microbiological result TAT before and after implementation of TLA and process
64 improvements, including implementation of matrix-assisted laser desorption ionization time-of-
65 flight mass spectrometry (MALDI-TOF) (Bruker Daltonik, Germany).23 The laboratory process
66 improvement preparation started in 2014 and the TLA system went live in May 2015. The entire
67 calendar years of 2013 and 2016 were used as pre- and post-periods, respectively, to evaluate
68 TAT before and after laboratory technology and process changes. The year 2016 was selected as
69 steady state to account for an implementation preparation period and a process-stabilization
70 period after TLA implementation in 2015. This study was approved by the Quality Improvement
71 Review Board at Texas Tech University Health Sciences Center. This work was conducted in a
72 manner consistent with the ideals set forth by the World Medical Association Declaration of
73 Helsinki regarding ethical conduct of research involving human subjects.

74

75 Process improvement in preparation for TLA

76 Review of SOPs

77 Process improvements and total laboratory automation at the study site went through a stepwise
78 and intricate process (see Figure 1). Initial steps were taken to ensure that process improvement
79 evaluations were generated/updated that align with the College of American Pathologists
80 guidelines for an accredited laboratory (https://www.cap.org/laboratory-
81 improvement/accreditation/laboratory-accreditation-program). In April 2014, all SOPs were
82 modified as needed according to procedural need; however, they remained aligned with
83 American Society of Microbiology (ASM)24 and Clinical Laboratory and Standards Institute

84 (CLSI) guidelines,[25] as well as community practice standards, in an effort that involved
85 networking with physician groups.

86 Staff education

87 All medical technologists (MTs) were actively engaged in professional education, assigned
88 specific topics, and responsible for retraining the department members on their respective roles
89 and monitoring compliance with the updated workflow practices. All MTs were educated and
90 tested on best practice as described in the *Clinical Microbiology Procedures Handbook*.[10]
91

92 Streamlined culture order code options and standardization of agar plate setup

93 The UMC microbiology laboratory standardized culture setups and streamlined the number of
94 order codes from 49 to 31. The standardization project resolved variability by narrowing plate
95 setups to a single option and setting clear expectations for reading plates. Completing these
96 projects simultaneously in November 2014 allowed for all MTs to be trained on all sources in
97 preparation for the automation line, where cultures would be prepared for reading during setup.
98 Digital imaging offered on the TLA system enabled plate images to be taken at ideal incubation
99 times. This allowed reading of the plates to be optimally timed by reviewing the images rather
100 than the plates themselves.[14, 18, 26]
101

102 Improved communication between laboratory and physician groups

103 Communication between laboratory management and physician/clinician groups during the TLA
104 implementation period was approached here in a manner similar to that reported previously.[27-
105 29] A diagnostic management team was created prior to commencing the transition to TLA. The
106 team consisted of laboratory management and different physician/clinician groups, and included

107 several goals. First, the team was created to ensure more consistent, open communication
108 between the laboratory and clinicians. Initial meetings between physician/clinician and
109 laboratory management included communication on process changes for ordering, testing, and
110 downstream activities of reporting, charting, and consultation. Team meetings covered
111 adjustments by the clinician to receive laboratory results in a reduced time frame in order to
112 convert the time savings to a potential benefit for patients through evidence-based practices.
113 Feedback from physician/clinician groups was received by the laboratory regarding TLA-related
114 issues such as patient charting based on the previous collection day. Related to charting,
115 discussion items included any changes in test selection and result interpretation based on TLA
116 implementation. Laboratory updates were provided to physician/clinician groups at team
117 meetings throughout the TLA implementation process. Post-implementation meetings revealed
118 physician/clinician perspectives on progress based on initial goal setting for processes including
119 reporting and charting. Feedback was also provided to the laboratory for continued improvement.
120

121 Pre- and Post-TLA sample processing

122 During the 2013 study period, specimens arrived for processing throughout the day and specimen
123 login to the laboratory information system was considered the initial time point for TAT (this
124 also applies to 2016). For the conventional plating technique, urine specimens were streaked
125 manually using calibrated loops onto blood and MacConkey agar plates and placed into
126 incubators. Specimen plating was performed in batches and incubation initially occurred
127 overnight (minimum of 18 hours). Plate reading was performed on four source benches,
128 including blood/cerebral spinal fluid, wound/tissue/body fluid, urine, and stool/respiratory, each
129 combining all plates into one batch during the morning. However, upon review, many plates

130 were being read early at 16 hours per work day from 6 am to 10 pm (i.e. many plates that were
131 prepared very early during the day shift [~6 am] were read at the end of the day shift [~10 pm]).
132 Spot testing, which included oxidase catalase, pyrrolidonyl arylamidase, desoxycholate, indole,
133 numerous latex agglutination tests, urease, and coagulase tests for Staphylococcus aureus, were
134 conducted when required for identification. The BD Phoenix™ system (Becton, Dickinson and
135 Company, BD Integrated Diagnostic Systems, Sparks, MD), A disk, P disk, RapID™ Systems
136 (Thermo Fisher, Waltham, MA), or API® ID Strips (bioMérieux, Marcy-l'Étoile, France) were
137 utilized for identification following all spot testing.
138
139 Kiestra TLA was implemented in May 2015 (Figure 1). Using TLA, specimens were inoculated
140 upon reception (no batching) onto the appropriate agar plate type by the BD Kiestra InoqulA+
141 system (InoqulA), and plates were automatically transported via BD Kiestra ProceedA to ReadA
142 Compact (incubation). Digital images of the plates were automatically acquired at 18, 42, and 66
143 hours depending on the sample type (i.e. 18 hours for day one, 42 hours for day two, and 66
144 hours for day three). Positive plates were sent to the ErgonomicA module, where a technologist
145 performed MALDI-TOF MS for identification. Spot testing was reduced to only indole and
146 desoxycholate for MALDI confirmation requirements, and coagulase and latex agglutination for
147 a more rapid ID of S. aureus and β-hemolytic streptococci, respectively. Bruker MALDI-TOF
148 MS was implemented in February 2016 for gram-negative IDs; gram-positive IDs were added in
149 October 2016, and anaerobe and yeast IDs were added in April 2017. MALDI-TOF MS replaced
150 identification by conventional methods, and times to result for positive specimens, preliminary
151 negatives, and antimicrobial test reporting were recorded as described above. All other spot
152 testing and ID methods were fully replaced with MALDI-TOF MS. A similar workflow was

153 utilized to identify cultures as negative. Plates identified as no growth or no pathogens at 18
154 hours were further incubated for an additional 24 hours for a total of 42 hours before a second
155 image analysis was performed. Times to result for positive specimens and preliminary negatives
156 were as described above.
157
158 Specimen Source and Organism Identification
159 Specimens were classified by source as blood, urine, wound, respiratory, intra-abdominal, and
160 other. The top ten common and clinically relevant bacteria seen in the laboratory were
161 Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae,
162 Streptococcus pyogenes (Group A), Streptococcus agalactiae (Group B), Pseudomonas
163 aeruginosa, Proteus mirabilis, Enterococcus faecalis, and Enterococcus faecium. From the
164 microbiology laboratory, results of 19.3% (2013) and 20.2% (2016) of the total results in each
165 respective year are included in this study. The analysis was restricted to positive specimen results
166 for mono-bacterial isolates of interest and negative culture results.[7, 18, 24, 30]
167
168 Definition of definitive results TAT
169 We assessed definitive positive organism identification (ID) TAT as time from laboratory login
170 of specimen to the earliest definitive positive result reporting time. Likewise, the TAT for
171 negative results was from laboratory login to the earliest definitive negative result report.
172
173 Data Source
174 De-identified digital microbiological data were captured in a research database (BD Insights)
175 created by Becton, Dickinson and Company (Franklin Lakes, NJ).[19, 20, 22] The dataset for the

176 current study included specimen collection time, source, laboratory login time, and culture
177 results reporting time.
178
179 Statistical analysis
180 We analyzed organism ID reporting time over a 24-hour spectrum. Definitive positive organism
181 ID and negative results TAT for pre- versus post-periods were compared. The $\chi 2$ test for
182 categorical variables and log-transformed t-test for continuous variables were utilized for
183 comparisons. A two-tailed p-value of <0.05 was considered statistically significant. All analyses
184 were conducted using SAS version 9.4 (SAS Institute, Cary, NC).

185 **RESULTS**

186 Overall 4,510 positive results were reported (Table 1). The mean TAT for all specimen types
187 was significantly shorter after TLA and process change implementation (2106) compared to pre-
188 TLA (2013) (all $p<0.05$).The overall TAT mean (standard deviation) was 43.3 (20.8) hours
189 versus 56.8 (24.3) hours for years 2016 and 2013, respectively. Figure 2 depicts the comparison
190 of cumulative distribution of TAT for positive IDs for the four most common specimen sources
191 (blood, urine, wound, and respiratory; all $p<0.05$). For blood specimens, the ID TAT was 53%
192 (2016) versus 17% (2013) by 48 hours from laboratory login time (Figure 2a). For samples
193 derived from urine, wound, and respiratory specimens, a higher percentage of results was
194 returned within 24 hours in 2016 compared to 2013. At least 40% of the urine, wound, and
195 respiratory specimens had TAT <36 hours in 2016, whereas in 2013, 40% of wound and
196 respiratory specimens had TAT >36 hours, and 40% of urine TAT exceeded 24 hours. For urine
197 specimens, the ID TAT was 51% (2016) versus 14% (2013) by 36 hours from laboratory login
198 time (Figure 2b). For respiratory specimens, the ID TAT was 59% (2016) versus 21% (2013) by
199 48 hours from laboratory login time (Figure 2c). For wound specimens, the ID TAT was 77%
200 (2016) versus 39% (2013) by 48 hours from laboratory login time (Figure 2d).

201

202 Overall 58,640 negative results were reported (Table 2). All sources except for respiratory and
203 "other" showed shortened TAT (all $p<0.05$). Figure 3 depicts the comparison of cumulative
204 distribution of negative result TAT for the four most common sources (blood, urine, wound, and
205 respiratory; all $p<0.05$). For blood specimens, the TAT was 95% (2016) versus 73% (2013) by
206 128 hours from laboratory login time (Figure 3a). TAT for specimens derived from urine and
207 wound showed the greatest reduction in 2016 compared to 2013. For urine specimens, the TAT

208 was 83% (2016) versus 10% (2013) by 36 hours from laboratory login time (Figure 3b). For
209 wound specimens, the ID TAT was 71% (2016) versus 36% (2013) by 96 hours from laboratory
210 login time (Figure 3c). For respiratory specimens, the negative results TAT was 79% (2016)
211 versus 86% (2013) by 96 hours from laboratory login time (Figure 3d). Negative results TAT
212 was less variable across the time frame categories for blood and respiratory between 2013 and
213 2016. However, the 80th percentile of TAT results for blood were returned within 126 to 128
214 hours in 2016, while those in 2013 were delayed to between 128 to 240 hours.

215 **DISCUSSION**

216 The results here suggest that TLA, in conjunction with process changes that facilitate TLA, led
217 to improvement in TAT for microbial ID. Although the observed shorter TAT was likely a joint
218 effect of intricate laboratory process improvement and implementation of the TLA, these results
219 are in agreement with previous studies that show a positive correlation between laboratory
220 automation and faster TAT. [18-22, 28] In general, the overall laboratory process improvement
221 interventions and TLA implementation (2016) led to shorter TAT for positive results compared
222 to 2013. For the highest volume specimen, urine cultures, pathogen ID TAT improved by an
223 average of 6.4 hours from 2013 to 2016. Since TLA processes and images the plates under
224 consistent incubation conditions, facilitating more robust growth,[18] a 16 to 30-hour growth
225 period was no longer necessary, which likely facilitated earlier ID. Blood cultures showed
226 significant improvement in TAT to pathogen positive ID by 19 hours, potentially enabling
227 providers to update their course of treatment by almost an entire day for patients with
228 bacteremia. In addition to urine and blood cultures, wound, respiratory, intra-abdominal, and
229 "other" cultures showed improvements of 20.6, 19.3, 12.2, and 22.5 hours, respectively (Table 1,
230 Figure 2). The use of ReadA Compact smart incubators, which reduce the incubation time
231 needed, plus MALDI-TOF for ID of gram-negative organisms, which reduces the time to
232 definitive ID, could contribute to improvement in TAT.

233

234 The implementation of laboratory process improvements incorporating TLA largely led to
235 reductions in TAT for negative culture results. For urines, the average time to report a negative
236 result in 2016 improved by 14 hours compared to 2013. Prior to TLA implementation, all
237 negative urine cultures were read manually, which necessitated pulling plates from the incubator

238 racks by hand. TLA standardizes incubation duration, so cultures are available to read at the
239 appropriate time as opposed to times that might be dictated by staff availability or other daily
240 workflow considerations. Digital imaging allows negative urines to be read on-screen, reducing
241 the manual labor of removing each plate from the incubator, and occurred at the 18-hour mark
242 with TLA. These approaches are consistent with current CLSI and ASM guidelines.[24, 25] Most
243 likely due to TLA capabilities including digital imaging and improved incubation times, the read
244 time for the majority of urine cultures was reduced to one day, with the exception of suprapubic,
245 straight catheter, cystoscopy, and nephrostomy sources. The results of negative wound cultures
246 were obtained an entire day sooner. Process changes prior to TLA included the removal of
247 thioglycolate broths from the wound cultures and a reduction in plate incubation times.
248 Improvements in TAT for respiratory and "other" were not observed for negative results. The
249 microbiology laboratory reported that respiratory and "other" specimens grew many isolates that
250 were more difficult to identify at first pass. Analyses involved with this study were focused on
251 single isolate cultures. Respiratory and "other" specimen types often grew isolates that were
252 mixed, overgrown, and/or mucoid. Subcultures were often necessary, delaying ID TAT. For the
253 mucoid specimens, repeated IDs were sometimes necessary, causing delays.
254
255 The significant time savings reported here were likely due to several factors. The overall
256 laboratory process improvement interventions, including SOP update, staff education, and
257 hospital-wide collaborations, are likely integral parts of the improvement in the shortened ID
258 TAT. In addition, the TLA system aided in reducing TAT through a number of key technical
259 components. Because ESwab™ (Copan Diagnostics Inc., Murrieta, CA, USA) and BD
260 Vacutainer™ (Becton, Dickinson and Company, Franklin Lakes, NJ) system-collected urines

261 could be fully automated, there was more than a 75% reduction in manual plate inoculation. The
262 system includes a plate-streaking module, the InoqulA, which has been shown to improve colony
263 isolation through automated plate streaking.[2, 4, 5] BD Kiestra TLA also features a component
264 called the ReadA Compact, a "smart" incubator, which does not require interruptions during the
265 incubation process in order to improve growth conditions.[7, 15] The physical connection between
266 the InoqulA module, ReadA Compact, and the ProceedA (a track that automates movement of
267 specimens between modules) minimizes the time that plates spend in the open air at room
268 temperature; plates are instead transported by the ProceedA to the ReadA Compact within
269 minutes. Moreno-Camacho et al demonstrated that the ReadA Compact uses enhanced organism
270 growth cycles and improved the rate of viable organisms available for further identification and
271 accurate susceptibility testing.[15] Standardization of specimen preparation and detection methods
272 has been shown to limit the potential for variability and to reduce manual reconciliation and
273 interpretation by individual technologists.[4]
274
275 Previously, cultures received a non-standardized 24 hours of incubation. Incubation times varied
276 from 16 to 30 hours of first incubation prior to TLA and process changes. Ongoing process
277 review and refinement to maintain adherence to current guidelines also precipitated further
278 removal of redundant or obsolete steps from manual processes (such as certain broth
279 incubations) for specific specimen types. Interestingly, we found that laboratory process
280 improvement and TLA implementation led to a more even distribution of clinical results during a
281 24-hour time spectrum (Figure S1). However, in line with previous discussion regarding work
282 distribution following TLA implementation,[31] we view a more even distribution of workflow
283 across a 24-hour work period as an indicator of improved workflow efficiency that reflects

284 reductions in unnecessary or excessive work and/or idle/waiting time. Automation of negative
285 result identification further allows laboratory personnel to focus on other important aspects of
286 clinical work, for example by allowing more time to read positive plates that require technical
287 skill. This idea is supported by previous work, as Greub et al estimated that 50–70% of the time
288 spent by full-time technicians may be saved by automation of pre-analytical sample preparation
289 and plate inoculation alone.[32]
290
291 This study has limitations. Since this is a retrospective observational study of a microbiology
292 laboratory TAT improvement in a real-world setting, each intervention was not pre-designed to
293 last long enough to allow for assessment of independent impact. The standardization and
294 workflow improvement activities were integral parts of TLA implementation, in which each
295 intervention often overlapped with other interventions. Thus, the impact of each component
296 attributable to the shortened TAT could not be measured independently. This resulted in an
297 inability to clearly delineate the proportion of TAT improvement attributable to process
298 improvement versus TLA. Likewise, MALDI-TOF was not fully integrated (to include yeast
299 identification along with Gram negative and Gram positive bacteria) until 2017, which
300 admittedly affected our capability to fully assess the impact of TLA at the time of study. A goal
301 for future studies will be to further investigate this continued quality improvement. Another
302 limitation is that we did not directly assess whether improved (shorter) TAT was associated with
303 improved patient outcomes, which is beyond the scope of this study. Nevertheless, performance
304 values following TLA using Kiestra have previously been demonstrated.[17, 26, 33] Furthermore,
305 previous work has been able to provide more direct evidence for a benefit of specific automation
306 components after the implementation TLA. For example, Theparee et al [20] were able to isolate

307 the impact of TLA (median ID TAT decrease of ~ 2 hours compared to pre-TLA) and of
308 MALDI-TOF (median ID TAT decrease of ~3 hours compared to TLA alone).[20] Mutters et al
309 combined TLA and MALDI-TOF together versus conventional testing. However, they
310 completely implemented the MALDI-TOF library at one time, as opposed to the stepwise
311 implementation of Gram negative, Gram positive, and yeast organisms over the course of one to
312 two years as occurred at this study site. In that study TLA combined with MALDI-TOF led to an
313 antibiotic switch in 12% of cases (in addition to those cases in which a switch was based on
314 Gram staining) as well as shortening the first 24-hour incubation time. Ultimately, however,
315 randomized, controlled trials will be required to better "…evaluate the actual benefits of an
316 automated system in terms of morbidity, mortality, and health care costs."[6]
317
318 *Conclusions*
319 In contrast to previous studies on the impact of TLA on clinical processes involving a single
320 specimen type,[7, 18, 19] this study describes the significant impact of TLA and related process
321 changes on decreased TAT in microbial ID across a broad range of specimen types. A
322 combination of TLA and associated workflow improvements contributes to shorter definitive
323 organism ID TAT across all specimen sources and shorter TAT for negative results for most
324 specimen sources. Overall, there was an average of approximately 13.5 hours improvement in
325 TAT to organism ID across all subsets of cultures for which data were analyzed. Additionally,
326 the overall TAT to negative result for all cultures, even with the regression of some cultures due
327 to process change, improved an average of approximately 7 hours. Future studies could further
328 investigate the relationship of operationalizing TLA technology and optimizing workflow, and

329 potentially identify positive impacts on patient care by informing and thereby enabling
330 physicians to make antibiotic therapy choices sooner.

ACKNOWLEDGEMENTS

The authors thank Devin S. Gary, PhD (Becton, Dickinson and Company, BD Life Sciences – Diagnostic Systems) and Andrea Gwosdow, PhD (Consultant for Becton, Dickinson and Company, BD Life Sciences – Diagnostic Systems), for insight, discussion, and review during the preparation of this manuscript. The individuals acknowledged here have no additional funding or additional compensation to disclose.

DISCLOSURES

This study was approved by the Quality Improvement Review Board of the study site. The researchers at Texas Tech University Health Sciences Center, University Medical Center, Lubbock, TX, and Becton, Dickinson and Co., Franklin Lakes, NJ conducted the analysis as their normal working responsibilities. YPT, LV, SK, DS, MW, and CA are current or former employees of Becton, Dickinson, and Company, the manufacturer of the BD Kiestra TLA system implemented by the study site. AE, CGO, SS, JN, and FL do not have any other disclosures. All authors provided final approval of the manuscript and agree to be accountable for the accuracy and integrity of this work.

REFERENCES

1. Lippi G, Da Rin G. Advantages and limitations of total laboratory automation: a personal overview. *Clin Chem Lab Med.* May 27 2019;57(6):802-811.

2. Croxatto A, Dijkstra K, Prod'hom G, Greub G. Comparison of Inoculation with the InoqulA and WASP Automated Systems with Manual Inoculation. *J Clin Microbiol.* Jul 2015;53(7):2298-2307.

3. Croxatto A, Prod'hom G, Faverjon F, Rochais Y, Greub G. Laboratory automation in clinical bacteriology: what system to choose? *Clin Microbiol Infect.* Mar 2016;22(3):217-235.

4. Froment P, Marchandin H, Vande Perre P, Lamy B. Automated versus manual sample inoculations in routine clinical microbiology: a performance evaluation of the fully automated InoqulA instrument. *J Clin Microbiol.* Mar 2014;52(3):796-802.

5. Iversen J, Stendal G, Gerdes CM, Meyer CH, Andersen CO, Frimodt-Moller N. Comparative Evaluation of Inoculation of Urine Samples with the Copan WASP and BD Kiestra InoqulA Instruments. *J Clin Microbiol.* Feb 2016;54(2):328-332.

6. Mutters NT, Hodiamont CJ, de Jong MD, Overmeijer HP, van den Boogaard M, Visser CE. Performance of Kiestra total laboratory automation combined with MS in clinical microbiology practice. *Ann Lab Med.* Mar 2014;34(2):111-117.

7. Dauwalder O, Landrieve L, Laurent F, de Montclos M, Vandenesch F, Lina G. Does bacteriology laboratory automation reduce time to results and increase quality management? *Clin Microbiol Infect.* Mar 2016;22(3):236-243.

8. Matthews S, Deutekom J. The future of diagnostic bacteriology. *Clin Microbiol Infect.* May 2011;17(5):651-654.

9. Carden R, Allsbrook K, Thomas R. An examination of the supply and demand for clinical laboratory professionals in the United States. *Transfusion.* Nov 2009;49(11 Pt 2):2520-2523.

10. Garcia E, Ali AM, Soles RM, Lewis DG. The American Society for Clinical Pathology's 2014 vacancy survey of medical laboratories in the United States. *Am J Clin Pathol.* Sep 2015;144(3):432-443.

11. Ward-Cook K. Medical laboratory workforce trends and projections: what is past is prologue. *Clin Leadersh Manag Rev.* Nov-Dec 2002;16(6):364-369.

12. Hawker CD. Nonanalytic Laboratory Automation: A Quarter Century of Progress. *Clin Chem.* Jun 2017;63(6):1074-1082.

13. Murray PR. Laboratory automation: efficiency and turnaround times. *Micro Austr.* 2014;35(1).

14. Humphrey G. MC, Gough H., Awadel-Kariem F.M. Experience with KIESTRA's Total Lab Automation solution to meet the challenge of universal MRSA screening for Lister Hospital, a large UK district general hospital. *Clinical Microbiology and Infection.* 2011;17(Supp 4).

15. Moreno-Camacho JL, Calva-Espinosa DY, Leal-Leyva YY, Elizalde-Olivas DC, Campos-Romero A, Alcántar-Fernández J. Transformation From a Conventional Clinical Microbiology Laboratory to Full Automation. *Laboratory Medicine.* 2017;49(1):e1-e8.

16. Thomson RB, Jr., McElvania E. Total Laboratory Automation: What Is Gained, What Is Lost, and Who Can Afford It? *Clin Lab Med.* Sep 2019;39(3):371-389.

17. Klein S, Nurjadi D, Horner S, Heeg K, Zimmermann S, Burckhardt I. Significant increase in cultivation of Gardnerella vaginalis, Alloscardovia omnicolens, Actinotignum schaalii, and Actinomyces spp. in urine samples with total laboratory automation. *Eur J Clin Microbiol Infect Dis.* Jul 2018;37(7):1305-1311.

18. Graham M, Tilson L, Streitberg R, Hamblin J, Korman TM. Improved standardization and potential for shortened time to results with BD Kiestra total laboratory automation of early urine cultures: A prospective comparison with manual processing. *Diagn Microbiol Infect Dis.* Sep 2016;86(1):1-4.

19. Yarbrough ML, Lainhart W, McMullen AR, Anderson NW, Burnham CD. Impact of total laboratory automation on workflow and specimen processing time for culture of urine specimens. *Eur J Clin Microbiol Infect Dis.* Dec 2018;37(12):2405-2411.

20. Theparee T, Das S, Thomson RB, Jr. Total Laboratory Automation and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Improve Turnaround Times in the Clinical Microbiology Laboratory: a Retrospective Analysis. *J Clin Microbiol.* Jan 2018;56(1).

21. Burckhardt I, Horner S, Burckhardt F, Zimmermann S. Detection of MRSA in nasal swabs-marked reduction of time to report for negative reports by substituting classical manual workflow with total lab automation. *Eur J Clin Microbiol Infect Dis.* Sep 2018;37(9):1745-1751.

22. Tabak YP, Vankeepuram L, Ye G, Jeffers K, Gupta V, Murray PR. Blood Culture Turnaround Time in U.S. Acute Care Hospitals and Implications for Laboratory Process Optimization. *J Clin Microbiol.* Dec 2018;56(12).

23. Zilberberg MD, Tabak YP, Sievert DM, et al. Using electronic health information to risk-stratify rates of Clostridium difficile infection in US hospitals. *Infect Control Hosp Epidemiol.* Jul 2011;32(7):649-655.

24. Carroll KC, Pfaller MA, Landry ML, et al. *Manual of Clinical Microbiology, Twelfth Edition*: American Society of Microbiology; 2019.

25. Patel JM, Cockerill FR, Eliopoulos GM, et al. CLSI. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Third Informational Supplement. CLSI document M100-S23. Wayne, PA: Clinical and Laboratory Standards Institute. 2014.

26. Heather CS, Maley M. Automated direct screening for resistance of Gram-negative blood cultures using the BD Kiestra WorkCell. *Eur J Clin Microbiol Infect Dis.* Jan 2018;37(1):117-125.

27. Buehler SS, Madison B, Snyder SR, et al. Effectiveness of Practices To Increase Timeliness of Providing Targeted Therapy for Inpatients with Bloodstream Infections: a Laboratory Medicine Best Practices Systematic Review and Meta-analysis. *Clin Microbiol Rev.* Jan 2016;29(1):59-103.

28. De Socio GV, Di Donato F, Paggi R, et al. Laboratory automation reduces time to report of positive blood cultures and improves management of patients with bloodstream infection. *Eur J Clin Microbiol Infect Dis.* Dec 2018;37(12):2313-2322.

29. Maurer FP, Christner M, Hentschke M, Rohde H. Advances in Rapid Identification and Susceptibility Testing of Bacteria in the Clinical Microbiology Laboratory: Implications for Patient Care and Antimicrobial Stewardship Programs. *Infect Dis Rep.* Mar 30 2017;9(1):6839.

30. Garcia L. *Clinical Microbiology Procedures Handbook, 3rd Edition*; 2010.

31. Burckhardt I. Laboratory Automation in Clinical Microbiology. *Bioengineering (Basel).* Nov 22 2018;5(4).

32. Greub G, Prod'hom G. Automation in clinical bacteriology: what system to choose? *Clin Microbiol Infect.* May 2011;17(5):655-660.

33. Croxatto A, Marcelpoil R, Orny C, Morel D, Prod'hom G, Greub G. Towards automated detection, semi-quantification and identification of microbial growth in clinical bacteriology: A proof of concept. *Biomed J.* Dec 2017;40(6):317-328.

Figure Legends

Figure 1: Microbiology Laboratory Quality Improvement Process Illustration. Kiestra TLA was implemented in May 2015.

Abbreviations: TLA, Total laboratory automation; MALDI-TOF, Matrix-assisted laser desorption/ionization-time of flight mass spectrometry; LIS, Laboratory information system; SOP, Standard operating proceedure.

Figure 2: Comparison of cumulative distribution of definitive positive bacterial pathogen ID turnaround time following login by most common source: a) blood, b) urine, c) respiratory, and d) wound. All values $p<0.05$.

Figure 3: Comparison of cumulative distribution of definitive negative culture results turnaround time following login by most common source: a) blood, b) urine, c) respiratory, and d) wound. All values $p<0.05$.

[a]The extended time reported for blood cultures reflects an initial growth/detection phase prior to plating.

Supplemental Figure 1: Organism ID reporting time distribution during a 24-hour spectrum.

Tables
Table 1

Table 1. Descriptive statistics for definitive positive bacterial pathogen ID turnaround time (hours)

Specimen	Year	n	Mean (SD)	Median (IQR)	p-value[a]
Blood	2013	759	70.6 (28.9)	62.8 (52.0, 74.5)	<.0001
	2016	882	51.2 (19.2)	46.6 (38.0, 59.1)	
Urine	2013	2,282	47.1 (14.9)	43.6 (38.0, 48.9)	<.0001
	2016	2,306	40.7 (18.8)	35.5 (27.7, 47.9)	
Wound	2013	1,160	60.2 (25.6)	58.6 (43.1, 69.2)	<.0001
	2016	869	39.6 (21.3)	32.8 (25.6, 47.0)	
Respiratory	2013	461	67.0 (23.5)	65.3 (49.8, 74.7)	<.0001
	2016	369	47.7 (24.9)	41.9 (28.1, 57.7)	
Intra-abdominal	2013	23	69.9 (28.8)	64.3 (53.1, 84.7)	0.0368
	2016	34	57.8 (32.1)	49.9 (25.7, 78.2)	
Other[b]	2013	56	75.1 (57.4)	64.5 (46.4, 89.8)	0.0013
	2016	50	52.6 (30.5)	46.1 (29.3, 69.7)	
Overall	2013	4,741	56.8 (24.3)	48.4 (41.1, 66.4)	<.0001
	2016	4,510	43.3 (20.8)	38.0 (28.7, 51.7)	

Abbreviations: SD, standard deviation; IQR, inter-quartile range (1st, 3rd quartile)

[a]Log-transformed t-test for continuous variables, utilized for comparisons of mean turnaround time.
[b]"Other" includes specimens from duodenal aspirate, ear, eye, quantitative tissue, quantitative bronchoscopy, environmental samples (surgical hardware, transfusion reactions), stool, cystic fibrosis cultures, dialysates, catheter tips, cerebral spinal fluid, genital, and throat.

Table 2

Table 2. Descriptive statistics for negative result turnaround time (in hours)

Specimen	Year	n	Mean (SD)	Median (IQR)	p-value[a]
Blood	2013	16,393	131 (54)	126 (122, 128)	<.0001
	2016	17,905	125 (6)	125 (123, 127)	
Urine	2013	8,115	44 (10)	45 (40, 47)	<.0001
	2016	8,880	30 (14)	26 (22, 32)	
Wound	2013	1,100	108 (40)	114 (74, 120)	<.0001
	2016	957	82 (43)	66 (50, 113)	
Respiratory	2013	1,204	62 (30)	50 (45, 64)	<.0001[b]
	2016	1,460	71 (36)	54 (47, 80)	
Intra-abdominal	2013	154	129 (26)	117 (113, 156)	<.0001
	2016	280	115 (40)	122 (103, 132)	
Other[c]	2013	613	121 (15)	118 (114, 123)	<.0001[b]
	2016	674	170 (27)	175 (164, 184)	
Overall	2013	27,579	101 (58)	121 (48, 127)	<.0001
	2016	30,156	94 (47)	123 (38, 126)	

Abbreviations: SD, standard deviation; IQR, inter-quartile range (1st, 3rd quartile)

[a]Log-transformed t-test for continuous variables, utilized for comparisons of mean turnaround time.
[b]For respiratory and “other” sources, the negative turnaround time was shorter in 2013.
[c]”Other” includes specimens from duodenal aspirate, ear, eye, quantitative tissue, quantitative bronchoscopy, environmental samples (surgical hardware, transfusion reactions), stool, cystic fibrosis cultures, dialysates, catheter tips, cerebral spinal fluid, genital, and throat.

Figures
Figure 1

Figure 1.



Figure 2


Figure 2.
Blood
Urine
Wound
Respiratory
Cumulative frequency
100%
80%
60%
40%
20%
0%
≤24
>24 to ≤36
>36 to ≤48
>48 to ≤72
>72 to ≤96
>96
Positive results turnaround time (hours)
2013
2016

Figure 3


Figure 3.
Blood
Cumulative frequency
100%
80%
60%
40%
20%
0%
≤120
>120 - ≤122
>122 - ≤124
>124 - ≤126
>126 - ≤128
>128 - ≤240
>240
Negative results turnaround time (hours)
2013
2016
Urine
Cumulative frequency
≤24
>24 to ≤36
>36 to ≤48
>48 to ≤72
>72 to ≤96
>96 to ≤120
>120
Negative results turnaround time (hours)
2013
2016
Wound
Cumulative frequency
≤24
>24 to ≤36
>36 to ≤48
>48 to ≤72
>72 to ≤96
>96 to ≤120
>120
Negative results turnaround time (hours)
2013
2016
Respiratory
Cumulative frequency
≤24
>24 to ≤36
>36 to ≤48
>48 to ≤72
>72 to ≤96
>96 to ≤120
>120
Negative results turnaround time (hours)
2013
2016

Supplemental Figure 1

Figure S1.